About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Pfizer’s Neuropathic Pain Drug Shows Reduced Efficacy in Its Phase III Trial

by Reshma Anand on November 26, 2015 at 5:52 PM
Font : A-A+

Pfizer’s Neuropathic Pain Drug Shows Reduced Efficacy in Its Phase III Trial

The US-based drug maker's lyrica developed to treat post-traumatic neuropathic pain has shown reduced efficacy in its final Phase III trial stage.

Currently there is no FDA-approved drug for treating chronic nerve pain caused by traumatic accidents or surgeries. The company had high hopes on this already existing FDA-approved drug Lyrica. But it has showed efficacy equal to only that of the placebo. The phase III trial is the final trial conducted by the drug developers for obtaining its approval from the FDA.

Advertisement


The generic name of Lyrica is Pregabalin and it was originally developed to treat general anxiety disorder and epilepsy. The drug has been already approved by the FDA for treating nerve pains caused due to various conditions such as diabetes, shingles, spinal cord injuries, fibromyalgia and epilepsy.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Placebo Effects: Rare Insights Thoracic Outlet Syndrome Exercising Tips For Nerve Pain Relief Allodynia 

Most Popular on Medindia

Blood Donation - Recipients Calculate Ideal Weight for Infants Drug Side Effects Calculator Nutam (400mg) (Piracetam) Find a Doctor Post-Nasal Drip Find a Hospital Blood - Sugar Chart Vent Forte (Theophylline) How to Reduce School Bag Weight - Simple Tips
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Pfizer’s Neuropathic Pain Drug Shows Reduced Efficacy in Its Phase III Trial Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests